{site_meta && site_meta.display_name} Logo

InvestorBrandNetwork (IBN)

The latest articles, editorials and news releases from InvestorBrandNetwork (IBN), a growing Investor Brand Platform.

RSS Feed for InvestorBrandNetwork (IBN)

BioMedNewsBreaks — Sunshine Biopharma Inc. (NASDAQ: SBFM) Closes $6 Million Public Offering

May 20, 2026Sunshine Biopharma (NASDAQ: SBFM) announced the closing of its previously announced public offering, generating approximately $6 million in gross proceeds before fees and expenses through the sale of 12 million common units, each including common stock or pre-funded warrants and two Series C warrants. The company said net proceeds will be used for general corporate purposes and working capital, with potential additional gross proceeds of approximately $12 million if the Series C warrants are fully exercised for cash, while Aegis Capital acted as exclusive placement agent.


NetworkNewsBreaks – Ideal Power Inc. (NASDAQ: IPWR) Secures $30 Million Financing to Accelerate B-TRAN Commercialization

May 20, 2026Ideal Power (NASDAQ: IPWR) announced a definitive agreement with institutional investors for a $30 million registered direct offering priced at the market under Nasdaq rules, with proceeds expected to support commercialization of its B-TRAN(R) bidirectional semiconductor power switch, including customer design-ins, custom development programs and initial production ramp efforts with strategic partners. Titan Partners, a division of American Capital Partners, is acting as sole placement agent for the financing, which the company said strengthens its balance sheet as it pursues growing opportunities tied to power efficiency demand across data center and industrial markets.


MissionIRNewsBreaks – Cardio Diagnostics Holdings, Inc. (NASDAQ: CDIO) CEO Highlights Growth Strategy, India Expansion on BioMedWire Podcast

May 20, 2026Cardio Diagnostics Holdings (NASDAQ: CDIO), took the spotlight in the latest episode of The BioMedWire Podcast, featuring CEO and Co-Founder Dr. Meesha Dogan discussing the company’s mission to improve cardiovascular disease prevention and early detection through precision medicine powered by epigenetics, genetics and artificial intelligence.


AINewsBreaks – Datavault AI Inc. (NASDAQ: DVLT) Forms DelivMeds AI Venture Through Wellgistics Partnership and Strategic Acquisitions

May 20, 2026Datavault AI (NASDAQ: DVLT) announced a binding term sheet with Wellgistics Health (NASDAQ: WGRX) to create DelivMeds AI, a healthcare platform combining AI-driven pharmacy optimization, blockchain-enabled smart contracts, biometric verification and direct-to-consumer healthcare delivery through three concurrent transactions, including an expanded PharmacyChain(TM) license, acquisition of QOLPOM intellectual property and a controlling stake in Tollo Health. The combined transactions carry an expected approximate asset value of $4 billion, subject to an independent fairness opinion, and are intended to support a national rollout of data-driven healthcare delivery and patient engagement solutions.


Cybersecurity Crisis Looms as Quantum Computing Matures

May 20, 2026For decades, modern cybersecurity has depended on encryption systems designed to keep sensitive information safe from hackers and cybercriminals. From online banking and email communication to medical records and cryptocurrency wallets, encryption acts as the invisible shield protecting digital life.


Researchers Create Less Toxic, More Effective Immunotherapy Against Blood Cancer

May 20, 2026University of North Carolina scientists have engineered immune cells that can destroy acute myeloid leukemia while sparing healthy blood tissue, overcoming a limitation that has plagued standard treatments, which have struggled to separate cancerous cells from normal cells. Immunologist Gianpietro Dotti and hematologist Paul Armistead directed research teams whose work appears in the journal Blood, offering an approach that may expand options for patients battling this deadly disease.


InvestorNewsBreaks – Telomir Pharmaceuticals (NASDAQ: TELO) Reports Peer-Reviewed Preclinical Data Supporting Telomir-Zn in Wilson’s Disease

May 20, 2026Telomir Pharmaceuticals (NASDAQ: TELO) announced publication of peer-reviewed preclinical data in Advances in Redox Research showing that Telomir-Zn delivered dose-dependent survival improvements and multiple therapeutic benefits in a Wilson’s disease model, including reduced oxidative stress, lower hepatic copper burden and improved liver function markers. The findings support the biological activity of Telomir-Zn in Wilson’s disease and expand the company’s scientific validation as it advances its lead triple-negative breast cancer program toward Phase 1/2 clinical initiation.


BioMedNewsBreaks — Cardio Diagnostics Holdings, Inc. (NASDAQ: CDIO) CEO Highlights Growth Strategy, India Expansion on BioMedWire Podcast

May 20, 2026Cardio Diagnostics Holdings (NASDAQ: CDIO), took the spotlight in the latest episode of The BioMedWire Podcast, featuring CEO and Co-Founder Dr. Meesha Dogan discussing the company’s mission to improve cardiovascular disease prevention and early detection through precision medicine powered by epigenetics, genetics and artificial intelligence.


AINewsBreaks – Safe Pro Group Inc. (NASDAQ: SPAI) Advances Edge AI Threat Detection Collaboration With Lantronix

May 20, 2026Safe Pro Group (NASDAQ: SPAI) announced progress in its AI-powered threat detection collaboration with Lantronix (Nasdaq: LTRX), marking a milestone in integrating Safe Pro’s SPOTD AI technology with Lantronix’s System-on-Module platform for real-time robotic edge processing. Following a 120-day development cycle, the collaboration positions the solution for broader deployment across next-generation autonomous air, ground and sea platforms, expanding Safe Pro’s reach in defense and commercial markets through edge-native AI processing that eliminates cloud dependence.


BioMedNewsBreaks — Scinai Immunotherapeutics Ltd. (NASDAQ: SCNI) Appoints Eilon Elmalem as Head of Yavne CDMO Facility

May 20, 2026Scinai Immunotherapeutics (NASDAQ: SCNI) announced the appointment of Eilon Elmalem as site head of its wholly owned subsidiary Scinai Biopharma Services’ Yavne CDMO facility, effective June 14, 2026. Elmalem, who has supported the company as an external consultant for the past two years, brings more than two decades of biotechnology and pharmaceutical operations experience and will oversee site operations and engineering activities as Scinai continues expanding its contract development and manufacturing platform.


NetworkNewsBreaks – Rail Vision Ltd. (NASDAQ: RVSN, FSE: C80) Subsidiary Achieves Quantum Error Correction Integration Milestone Using Google Quantum AI Dataset

May 20, 2026Rail Vision (NASDAQ: RVSN, FSE: C80) announced that its majority-owned subsidiary, Quantum Transportation Ltd. , has successfully delivered a working integration layer that incorporates a publicly accessible experimental surface-code dataset from Google Quantum AI into its patent-pending quantum error correction transformer pipeline.